# US 2013/0296287 A1 · Focal photodynamic therapy methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296287 A1
- Document ID: US20130296287A1
- Status: Published application
- Kind: A1
- Application number: 13/682,694
- Filed: 2012-11-20
- Published: 2013-11-07
- Earliest claimed: 2011-03-11
- Assignees: Steba Maor SA
- Applicants: Steba Maor SA
- Inventors: Suzy Charbit; Bertrand Gaillac; Lucien Abenhaim
- Web page: https://patentgrep.com/patent/US20130296287A1

## CPC

- A61N 5/062: {Photodynamic therapy, i.e. excitation of an agent}
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/555: containing heavy metals, e.g. hemin, hematin, melarsoprol
- A61K 41/0057: {Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent}
- A61N 5/0603: {for treatment of body cavities}
- G16H 20/17: delivered via infusion or injection
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- A61N 2005/0612: {using probes penetrating tissue; interstitial probes}
- A61N 2005/0627: {Dose monitoring systems and methods}
- A61N 2005/063: {comprising light transmitting means, e.g. optical fibres}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Improved methods of treating prostate cancer by vascular-targeted photodynamic therapy, and improved methods of planning treatment, are presented using a light density index to plan and guide effective treatment.

## Claims

### Claim 1

A method of treating prostate cancer, comprising:
systemically administering a photosensitizing agent to a patient having a prostate tumor;
activating the photosensitizing agent by delivering light of appropriate wavelength through at least one optical fiber positioned proximal to the tumor,
wherein the dose of light delivered is at or above a prior-determined treatment-effective light density index (LDI) threshold.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent.

### Claim 3 (depends on 2)

The method of claim 2, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage.

### Claim 4 (depends on 3)

The method of claim 3, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, and same wavelength of delivered light.

### Claim 5 (depends on 1)

The method of claim 1, wherein the photosensitizing agent is Palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2-sulfoethyl)amide, or pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein the photosensitizing agent is Palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2-sulfoethyl)amide dipotassium salt.

### Claim 7 (depends on 1)

The method of claim 1, wherein the photosensitizing agent is administered intravenously.

### Claim 8 (depends on 7)

The method of claim 7, wherein the photosensitizing agent is Palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2-sulfoethyl)amide, or pharmaceutically acceptable salts thereof, administered intravenously at 3-6 mg/kg.

### Claim 9 (depends on 8)

The method of claim 8, wherein the photosensitizing agent is administered at a dose of 4 mg/kg.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dose of light delivered is 200 J/cm and the LDI threshold is 1.0.

### Claim 11 (depends on 1)

The method of claim 1, wherein light is delivered through a plurality of optical fibers.

### Claim 12 (depends on 11)

The method of claim 11, wherein the optical fibers are positioned using a brachytherapy template.

### Claim 13 (depends on 1)

The method of claim 1, wherein light is delivered at a wavelength that approximates an absorption maximum of the systemically administered photosensitizing agent.

### Claim 14

In a method of photodynamic treatment of prostate cancer in which a photosensitizing agent is administered systemically and then activated by delivery of light of appropriate wavelength through at least one optical fiber positioned proximal to the tumor, the improvement comprising:
delivering a light dose at or above a prior-determined treatment-effective light density index (LDI) threshold.

### Claim 15 (depends on 14)

The method of claim 14, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage.

### Claim 17 (depends on 16)

The method of claim 16, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, and same wavelength.

### Claim 18 (depends on 14)

The method of claim 14, wherein the photosensitizing agent is Palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2-sulfoethyl)amide, or pharmaceutically acceptable salts thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein the photosensitizing agent is Palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2-sulfoethyl)amide dipotassium salt.

### Claim 20 (depends on 14)

The method of claim 14, wherein the photosensitizing agent is administered intravenously.

### Claim 21 (depends on 20)

The method of claim 20, wherein the photosensitizing agent is Palladium 31-oxo-15-methoxycarbonylmethyl-rhodobacteriochlorin 131-(2-sulfoethyl)amide, or pharmaceutically acceptable salts thereof, administered intravenously at 3-6 mg/kg.

### Claim 22 (depends on 21)

The method of claim 21, wherein the photosensitizing agent is administered at a dose of 4 mg/kg.

### Claim 23 (depends on 22)

The method of claim 22, wherein the light is delivered at 200 J/cm and the LDI threshold is 1.0.

### Claim 24 (depends on 14)

The method of claim 14, wherein light is delivered through a plurality of optical fibers.

### Claim 25 (depends on 24)

The method of claim 24, wherein the optical fibers are positioned using a brachytherapy template.

### Claim 26 (depends on 14)

The method of claim 14, wherein light is delivered at a wavelength that approximates an absorption maximum of the systemically administered photosensitizing agent.

### Claim 27

In a method of planning photodynamic therapy of prostate cancer in a patient, the improvement comprising:
setting the total length of illuminating fiber to be used for treatment based upon the planned treatment volume (PTV) and a prior-determined treatment-effective light density index threshold.

### Claim 28 (depends on 27)

The method of claim 27, wherein the total length of illuminating fiber is calculated as the product of PTV and prior-determined treatment-effective light density index threshold or scalar multiple thereof.

### Claim 29 (depends on 28)

The method of claim 28, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent.

### Claim 30 (depends on 29)

The method of claim 29, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage.

### Claim 31 (depends on 30)

The method of claim 30, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, and same wavelength of delivered light.

### Claim 32 (depends on 31)

The method of claim 31, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, same irradiating light wavelength, and same light density.

### Claim 33

A computer program product comprising a computer usable medium having computer readable program code embodied therein, the computer readable program code adapted to be executed by a computer to implement a method for producing a patient-specific treatment plan for photodynamic therapy of prostate cancer, the method comprising:
setting the total length of illuminating fibers needed for effective therapy based upon the planned treatment volume (PTV) and a prior-determined treatment-effective light density index threshold.

### Claim 34 (depends on 33)

The computer program product of claim 33, wherein the total length of illuminating fibers is calculated as the product of PTV and prior-determined treatment-effective light density index threshold, or scalar multiple thereof.

### Claim 35 (depends on 34)

The computer program product of claim 34, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent.

### Claim 36 (depends on 35)

The computer program product of claim 35, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage.

### Claim 37 (depends on 36)

The computer program product of claim 36, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, and same wavelength of delivered light.

### Claim 38 (depends on 37)

The computer program product of claim 37, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, same irradiating light wavelength, and same light density.

### Claim 39

Assistance method, implemented by computer, for the planning of treatment of a patient by photodynamic therapy, in which a predefined photosensitizing agent must be administered to the patient, and then subjected to illumination at a predetermined wavelength through at least one illuminating fiber designed to be introduced over a length of insertion into the treatment area, characterized in that it includes the following steps:
calculating the planned treatment volume, PTV, of the treatment area; determining a treatment-effective light density index, LDI, threshold; and then
setting the total length of said at least one illuminating fiber to be used for treatment based upon the planned treatment volume, PTV, and said prior-determined treatment-effective light density index threshold.

### Claim 40 (depends on 39)

The assistance method of claim 39, wherein the total length of illuminating fiber is calculated as the product of PTV and prior-determined treatment-effective light density index threshold or scalar multiple thereof

### Claim 41 (depends on 40)

The method of claim 40, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent.

### Claim 42 (depends on 41)

The assistance method of claim 41, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage.

### Claim 43 (depends on 42)

The assistance method of claim 42, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, and same wavelength of delivered light.

### Claim 44 (depends on 43)

The assistance method of claim 43, wherein the treatment-effective LDI threshold is prior-determined from historical data from use of the same photosensitizing agent, administered at the same systemic dosage, same irradiating light wavelength, and same light density.
